New radioactive drug aims to destroy bladder tumors without surgery

NCT ID NCT07260162

Not yet recruiting Disease control Sponsor: Institut Cancerologie de l'Ouest Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new drug called ATO-101 for a type of bladder cancer that hasn't responded to standard treatments. The drug delivers a short-range radioactive particle directly into the bladder to kill cancer cells while sparing healthy tissue. About 24 patients will receive the drug to find the safest dose and see if it shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ATO-101 (a radioactive antibody that targets bladder cancer cells)
What this could lead to: If it works, this could offer a new treatment option for patients with bladder cancer that hasn't responded to standard therapy, potentially avoiding bladder removal.
What could go wrong: This is a very early (Phase 1) trial with only 24 participants, so it's too soon to know if it's safe or effective. The drug uses radiation, which could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-invasive bladder urothelial carcinoma Non-Muscle Invasive Bladder Neoplasms urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER

Contacts and locations

Locations

Institut de Cancérologie de l'Ouest

Saint-Herblain, Loire Atlantique, 44800, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.